SUMMARY Lipodystrophies are characterized by complete or selective loss of adipose tissue and can be acquired or inherited. Familial partial lipodystrophy (FPLD) is a hereditary lipodystrophy commonly caused by mutations in the LMNA gene. Herein, we report two cases of FPLD associated with podocytopathies. Patient 1 was diagnosed with FPLD associated with the heterozygous p.Arg482Trp variant in LMNA and had normal glucose tolerance and hyperinsulinemia. During follow-up, she developed nephrotic-range proteinuria. Renal biopsy was consistent with minimal change disease. Patient [...] SUMMARY Lipodystrophies are characterized by complete or selective loss of adipose tissue and can be acquired or inherited. Familial partial lipodystrophy (FPLD) is a hereditary lipodystrophy commonly caused by mutations in the LMNA gene. Herein, we report two cases of FPLD associated with podocytopathies. Patient 1 was diagnosed with FPLD associated with the heterozygous p.Arg482Trp variant in LMNA and had normal glucose tolerance and hyperinsulinemia. During follow-up, she developed nephrotic-range proteinuria. Renal biopsy was consistent with minimal change disease. Patient
Background: Renal angiomyolipomas hemorrhage is strongly associated with their size and vascular constitution. Since previous studies showed that mTOR inhibitors can differentially act in distinct cell lines, we analyzed the effects of sirolimus on the volume of different components of angiomyolipomas in patients with tuberous sclerosis complex, including vascular structures. We retrospectively analyzed 23 angiomyolipomas from 10 patients treated with sirolimus. An approach based on a Hounsfield-unit threshold was used to classify angiomyolipomas in fat-rich, fat-poor and intermediate-fat tumors, and to categorize tumor compartments in fat rich, fat poor, intermediate fat and highly vascularized. Diameter variations were measured to assess the effects on aneurysmatic/ectatic vascular formations. Results: Volume reduction following treatment with sirolimus was higher in fat-poor than fat-rich angiomyolipomas. Tumor reduction was mainly determined by decrease of the fat-poor and highly-vascularized compartments, with a lesser contribution of the intermediate-fat component, while the volume of the fat-rich compartment increased. Broad liposubstitution was observed in some tumors. Massive reduction of aneurysmatic/ectatic vascular structures was observed, with disappearance of such lesions in most cases. Conclusions: Our study showed that sirolimus reduces the size of angiomyolipomas by decreasing primarily their highly-vascularized and fat-poor compartments. This effect is associated with a remarkable reduction of tumoral aneurysms/ectatic vessels and other vascular structures. Our findings revealed, therefore, the likely mechanism responsible for the reported risk-decreasing effect of mTOR inhibitors on angiomyolipoma bleeding. Our findings also expand the understanding the biology of this tumor, supporting a role for mTOR in maintenance, and maybe assembling, of blood vessels in angiomyolipomas.
Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder resulting from pathogenic variants in the TSC1 or TSC2 genes, leading to hyperactiva